PL1660484T3 - Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1 - Google Patents

Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1

Info

Publication number
PL1660484T3
PL1660484T3 PL04739120T PL04739120T PL1660484T3 PL 1660484 T3 PL1660484 T3 PL 1660484T3 PL 04739120 T PL04739120 T PL 04739120T PL 04739120 T PL04739120 T PL 04739120T PL 1660484 T3 PL1660484 T3 PL 1660484T3
Authority
PL
Poland
Prior art keywords
sup
methyl
alpha
pyrrolopyridines
adrenergic agonists
Prior art date
Application number
PL04739120T
Other languages
English (en)
Inventor
Michael Patrick Dillon
Clara Jeou Jen Lin
Amy Geraldine Moore
Counde O'yang
Yansheng Zhai
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1660484T3 publication Critical patent/PL1660484T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04739120T 2003-05-09 2004-04-30 Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1 PL1660484T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46925503P 2003-05-09 2003-05-09
EP04739120A EP1660484B1 (en) 2003-05-09 2004-04-30 Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists
PCT/EP2004/004609 WO2004099189A1 (en) 2003-05-09 2004-04-30 Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists

Publications (1)

Publication Number Publication Date
PL1660484T3 true PL1660484T3 (pl) 2009-02-27

Family

ID=33435226

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04739120T PL1660484T3 (pl) 2003-05-09 2004-04-30 Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1

Country Status (15)

Country Link
US (1) US6979696B2 (pl)
EP (1) EP1660484B1 (pl)
JP (1) JP4454622B2 (pl)
KR (1) KR100751163B1 (pl)
CN (1) CN100378097C (pl)
AT (1) ATE406363T1 (pl)
AU (1) AU2004235923B2 (pl)
BR (1) BRPI0410237A (pl)
CA (1) CA2523253C (pl)
DE (1) DE602004016177D1 (pl)
ES (1) ES2313019T3 (pl)
MX (1) MXPA05011841A (pl)
PL (1) PL1660484T3 (pl)
RU (1) RU2313524C2 (pl)
WO (1) WO2004099189A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050072812A (ko) * 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
TW200602317A (en) * 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
JP2009510066A (ja) * 2005-09-29 2009-03-12 ワイス 血管運動症状（ｖｍｓ）の治療のためのモノアミン再取り込みのモジュレータである１−（１ｈ−インドール−１−イル）−３−（メチルアミノ）−１−フェニルプロパン−２−オール誘導体および関連の化合物
ATE442368T1 (de) * 2005-11-30 2009-09-15 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
HUE030393T2 (en) 2010-12-28 2017-05-29 Sanofi Sa New pyrimidine derivatives, a process for their preparation, and their pharmaceutical use as inhibitors of AKT (PKB) phosphorylation
CN102702196B (zh) * 2012-06-13 2015-01-14 南京药石药物研发有限公司 3-甲基-7-氮杂吲哚的合成方法
KR102129842B1 (ko) * 2013-10-02 2020-07-06 주식회사 대웅제약 술포닐인돌 유도체 및 이의 제조방법
WO2016014426A1 (en) * 2014-07-21 2016-01-28 The Arizona Board Of Regents Organic reactions
WO2024080361A1 (ja) * 2022-10-14 2024-04-18 株式会社 三和化学研究所 イミダゾール誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
GB9011335D0 (en) 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
CA2164009A1 (en) 1993-06-14 1994-12-22 Robert L. Dow Secondary amines as antidiabetic and antiobesity agents
JPH0887346A (ja) * 1994-09-14 1996-04-02 Chino Kogyo:Kk パソコン等デスク上を活用する為の卓上台座器具
CN1237160A (zh) 1996-11-14 1999-12-01 辉瑞大药厂 取代的吡啶的制备方法
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
WO2001070687A1 (de) 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können
DE10106214A1 (de) * 2001-02-10 2002-08-14 Boehringer Ingelheim Pharma Neue Alkyl-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz
BR0307406A (pt) * 2002-02-01 2004-12-28 Hoffmann La Roche Indóis substituìdos como agonistas alfa-1

Also Published As

Publication number Publication date
ES2313019T3 (es) 2009-03-01
KR100751163B1 (ko) 2007-08-22
RU2313524C2 (ru) 2007-12-27
WO2004099189A1 (en) 2004-11-18
AU2004235923B2 (en) 2008-01-24
DE602004016177D1 (de) 2008-10-09
CN1784397A (zh) 2006-06-07
CA2523253A1 (en) 2004-11-18
MXPA05011841A (es) 2006-01-26
RU2005138143A (ru) 2006-08-10
AU2004235923A1 (en) 2004-11-18
KR20060015590A (ko) 2006-02-17
CN100378097C (zh) 2008-04-02
EP1660484A1 (en) 2006-05-31
ATE406363T1 (de) 2008-09-15
BRPI0410237A (pt) 2006-05-09
CA2523253C (en) 2010-06-22
US6979696B2 (en) 2005-12-27
JP4454622B2 (ja) 2010-04-21
US20040224973A1 (en) 2004-11-11
JP2006525970A (ja) 2006-11-16
EP1660484B1 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
PL361361A1 (pl) Podstawione 1-aminoalkilolaktamy i ich zastosowanie jako antagonistów receptora muskarynowego
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
PL361282A1 (pl) Podstawione 1-aminoalkilo-laktamy i ich zastosowanie jako antagonistów receptora muskarynowego
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
TW200613243A (en) Novel compounds
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
SI1506185T1 (sl) Spojine in njihova uporaba kot inhibitorji 5-HT
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
UA95223C2 (ru) Производные пиридопиримидина, их получение, их применение в терапии
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
PL374019A1 (pl) Pochodne benzoksazyny jako modulatory 5-HT6 i ichzastosowanie
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
PL1660484T3 (pl) Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
CA2292921A1 (en) Aryl carboxylic acid and tetrazole derivatives
TNSN04105A1 (en) Imidazoquinoline derivatives
AU2001258489A1 (en) Novel vitronectin receptor antagonists